Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + FMD for Multiple Myeloma with Secondary Extramedullary Disease
ChiCTR2500107131Phase 3Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax in multiple myeloma (MM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Objective remission rate and Duration of remission. Started Aug 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500107131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107131.